BUSINESS AREA
Labtech
The Labtech business area provides products, solutions and services in fields such as diagnostics, biomedical research and laboratory analysis. The business area consists of two business units: Biomedical and Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies in Europe.
| Q1 | Q1 | ∆ | Apr 2025- | Full year | |
| SEKm | 2026 | 2025 | % | Mar 2026 | 2025 |
| Net sales | 985 | 989 | -0 | 3,949 | 3,953 |
| Organic growth, % | 2 | 12 | 5 | ||
| EBITA | 129 | 120 | 7 | 504 | 495 |
| EBITA margin, % | 13.1 | 12.1 | 12.8 | 12.5 | |
| Adjusted EBITA | 129 | 120 | 7 | 504 | 495 |
| Adjusted EBITA margin, % | 13.1 | 12.1 | 12.8 | 12.5 |
FIRST QUARTER
Net sales in Labtech amounted to SEK 985 million (989) in the quarter. Adjusted for exchange rate effects, net sales increased by 3 percent, of which organic growth was 2 percent and acquired growth was 1 percent. Exchange rate effects had a negative impact of 3 percent on net sales.
EBITA increased by 7 percent to SEK 129 million (120), corresponding to an EBITA margin of 13.1 percent (12.1). Exchange rate effects had a negative impact of 3 percent on EBITA, corresponding to SEK 4 million.
In Labtech, margins improved significantly compared with the first quarter of 2025. Previously won tenders continue to contribute positively. Sales in, for example, blood gas, immunology and Alzheimer’s diagnostics are developing well. New advanced products are continuously being added to the product portfolios.
The vast majority of AddLife’s companies generate their sales in Europe, but some companies also have sales in the United States. Sales in the United States have been adversely affected by decreasing research grants.
In Europe, we have for some time seen a gradual improvement in research funding, and this trend has strengthened during the quarter. This positive trend has led to increased sales of research instruments and consumables during the quarter.
Genomics and gene sequencing
One example of an area with advanced products is gene sequencing, which involves mapping DNA, the genetic information that governs how our bodies function. With modern technology, it is now possible to map all or parts of the genome quickly and cost‑effectively. This has rapidly made gene sequencing an indispensable tool in research, diagnostics and healthcare.
Based on this new technology, new and even more detailed methods have emerged. With single‑cell technology, gene activity in individual cells can be studied instead of analysing an average of millions of cells. This makes it possible to detect differences between cells that were previously hidden, for example which tumour cells cause disease or which immune cells respond to treatment. With spatial transcriptomics, it is also possible to see where in the tissue different genes are active and to link gene expression to their exact position, for example in a tumour or in brain tissue. This provides an entirely new, more detailed understanding of how diseases arise and develop. Together, these techniques enable the next generation of precision medicine.
AddLife’s companies are active across this entire area and offer products for gene sequencing, single‑cell analyses and spatial transcriptomics from more than ten leading international suppliers. The offering includes instruments, reagents and software, combined with qualified support and service for customers in research, diagnostics and healthcare, primarily in Scandinavia, Central and Eastern Europe and Southern Europe.
Total sales of sequencing‑related products and services for AddLife amounted to approximately SEK 400 million in 2025. The market is expected to grow by around 10–15 percent per year in the coming years, driven by increased use within precision medicine, expanded cancer and infectious disease diagnostics, and a rapidly growing research market for single‑cell and spatial techniques. Overall, this is an area with good margins, high structural growth and significant potential for AddLife’s companies to continue gaining market share.
Precision medicine
Some key areas of application within precision medicine are:
- Cancer treatment: Genetic alterations in tumours are mapped to enable more targeted treatment methods, and single‑cell and spatial methods are used to understand the composition and microenvironment of the tumour.
- Rare diseases: Whole‑genome and exome sequencing help to identify genetic causes in previously unexplained disease conditions.
- Infectious disease diagnostics: The genomes of bacteria and viruses are analysed to rapidly trace the spread of infection and detect antibiotic resistance.
- Prenatal diagnostics: In NIPT (Non‑Invasive Prenatal Testing), sequencing is used on a simple blood sample to enable early detection of chromosomal abnormalities.
>10
LEADING SUPPLIERS
400
SALES SEK MILLION, 2025
10-15%
MARKET GROWTH